| abstract |
The use of a compound of formula (I), wherein X represents O, S, C=O or a bond; p and q independently represent 0-4; R?1 and R2¿ each independently represent hydrogen, C¿1-6?alkyl, C3-6cycloalkyl or C3-6cycloalkylC1-4alkyl; n is 1, 2, 3 or 4; and Ar represents phenyl optionally substituted by 1 to 3 substituents selected from: halo, C1-4alkyl, C1-4alkoxy, C1-2alkylenedioxy, trifluoromethyl, trifluoromethoxy, CN, NO2, amino, mono- or di- alkylamino and Ph(Alk?1)¿rY(Alk2)s- where Ph is optionally substituted phenyl, Y is a bond, oxygen or a carbonyl group, Alk1 and Alk2 independently represent C¿1-4?alkyl which may be straight or branched and r and s are independently 0 or 1, provided that the length of (Alk?1)¿rY(Alk2)s does not exceed 5 atoms, and pharmaceutically acceptable salts thereof; in the manufacture of a medicament for the treatment of a disorder wherein a clacium channel antagonist is indicated, e.g. ischaemic stroke. Certain novel compounds within formula (I) are also claimed. |